Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sienna Biopharmaceuticals (SNNAQ)
OTHER OTC:SNNAQ
Holding SNNAQ?
Track your performance easily
SNNAQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.01
Volume20.00
Average Volume (3M)N/A
Market Cap
$31.00
Enterprise Value-$11.54M
Total Cash (Recent Filing)$11.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-2.17
Next Earnings
Oct 09, 2020EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,907,542
10 Day Avg. Volume2
30 Day Avg. VolumeN/A
Standard Deviation19.81
R-Squared0.05
Alpha2.89
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-183.25
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
7.71% Mutual Funds
<0.01% Other Institutional Investors
92.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SNNAQ FAQ
What was Sienna Biopharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Sienna Biopharmaceuticals’s market cap?
Currently, no data Available
When is Sienna Biopharmaceuticals’s upcoming earnings report date?
Sienna Biopharmaceuticals’s upcoming earnings report date is Oct 09, 2020 which is 1504 days ago.
How were Sienna Biopharmaceuticals’s earnings last quarter?
Sienna Biopharmaceuticals released its earnings results on May 08, 2019. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
Is Sienna Biopharmaceuticals overvalued?
According to Wall Street analysts Sienna Biopharmaceuticals’s price is currently Overvalued.
Does Sienna Biopharmaceuticals pay dividends?
Sienna Biopharmaceuticals does not currently pay dividends.
What is Sienna Biopharmaceuticals’s EPS estimate?
Sienna Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sienna Biopharmaceuticals have?
Sienna Biopharmaceuticals has 30,908,000 shares outstanding.
What happened to Sienna Biopharmaceuticals’s price movement after its last earnings report?
Sienna Biopharmaceuticals reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sienna Biopharmaceuticals?
Currently, no hedge funds are holding shares in SNNAQ
---
Company Description
Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.
---
Aquestive Therapeutics
―
Eloxx Pharmaceuticals
―
Moleculin Biotech
―
Outlook Therapeutics
―
---